Nyxoah SA NYXH

Nyxoah SA announced CFO John Landry will step down on October 2, 2026, with Loïc Moreau, Nyxoah’s President International and former CFO, serving as interim CFO during the search for a permanent successor. Moreau previously led Nyxoah’s finance function and has over 20 years of experience, including roles at GSK. The company pledges a smooth transition given Moreau’s familiarity with the business and its growth strategy. Nyxoah reaffirmed its full-year 2026 guidance: revenue €36–€40 million; gross margin 60–62%; total operating expenses €99–€102 million; non-GAAP cash operating expenses €88–€90 million. Nyxoah’s Genio system is CE-marked and FDA-approved (as of 2025) with ongoing development of its indications and pipeline. Internal CFO transition with an internal interim appointee and reaffirmed guidance suggests limited near-term impact.

Nyxoah SA launches the BREATHE Study to gather real-world evidence on its Genio system for obstructive sleep apnea treatment, seeking to accelerate commercial adoption through clinical data. BREATHE Study launch targets real-world data to support Genio adoption and market expansion.

Nyxoah SA shares declined despite the first Genio system implant in the United States under the BREATHE clinical trial. U.S. trial implant represents clinical milestone with moderate potential to affect future regulatory path and sentiment.

Nyxoah SA implanted the first patient in the BREATHE U.S. Post-Approval Study of the Genio System. First U.S. post-approval implantation advances Genio system validation and market entry.

Nyxoah SA shares jumped after its Genio system met primary endpoints in a CCC patient study. Positive Genio trial outcomes in CCC patients enable regulatory progress and expand addressable market.

Nyxoah SA's ACCCESS U.S. Pivotal Study met primary safety and efficacy endpoints in complete concentric collapse patients. Pivotal study success advances regulatory approval prospects and U.S. market entry for Nyxoah's core sleep apnea therapy.

Nyxoah SA reported 22% sequential US revenue growth in Q2 2026 earnings call highlights alongside a $110M figure. US revenue surge signals accelerating commercial adoption and improved market traction.

Nyxoah SA released Q2 earnings call highlights covering financial results, operational progress and forward outlook for its medical device business. Quarterly earnings updates supply fresh financial metrics and guidance that can shift near-term investor views without altering long-term company trajectory.

Nyxoah SA released financial and operating results for the second quarter and first half of 2026. Quarterly results supply performance metrics that shape near-term valuation and sentiment.

Nyxoah SA highlighted strong U.S. launch traction for its Genio device along with stable reimbursement conditions during its Investor Day. U.S. launch traction and reimbursement stability for Genio boost Nyxoah's market entry and revenue outlook.

Nyxoah SA (NYXH) stock fair value lowered after capital raise and analyst caution. Capital raise signals dilution risk and analyst caution points to weaker sentiment that can pressure near-term performance.

Nyxoah SA announced preliminary results for the second quarter of 2026. Quarterly results releases directly affect revenue visibility, cash position, and near-term stock valuation for Nyxoah.

Analyst cuts and capital concerns reduce Nyxoah SA stock fair value. Analyst downgrades and capital concerns directly pressure near-term valuation and sentiment without altering core operations.

Nyxoah SA receives $15 million from the European Investment Bank. The capital infusion strengthens Nyxoah's financial position and supports development initiatives.

Nyxoah SA raises $110 million in aggregate financings to accelerate Genio's U.S. commercial launch. $110 million financing directly funds U.S. commercial rollout of core Genio product and materially strengthens growth trajectory.

Nyxoah SA (NYXH) closed its underwritten public offering. Offering closure supplies fresh capital while diluting equity and altering balance sheet for ongoing operations.

Nyxoah SA prices $95 million underwritten public offering. Public offering supplies growth capital but dilutes shareholders and pressures near-term stock price.

Nyxoah SA enters a new phase of long-term value creation. Strategic repositioning supports moderate growth and market positioning without immediate fundamental shifts.

Nyxoah SA (NYXH) Q1 2026 earnings call highlights strong U.S. performance amid key operational updates. Strong U.S. results in Q1 2026 earnings call signal major positive shifts in revenue growth and market positioning.

Nyxoah SA held its Q1 2026 earnings call, covering financial results, operational updates, and forward-looking statements for the company's sleep apnea treatment devices. Quarterly earnings provide updated financial metrics and guidance that can shift near-term investor views but rarely alter long-term company trajectory on their own.

Nyxoah SA (NYXH) released Q1 earnings call highlights detailing financial results, operational updates, and forward guidance. Q1 earnings highlights disclose key financial metrics and strategic outlook that drive investor sentiment and stock trajectory.

Nyxoah SA (NYXH) reported first quarter 2026 financial and operating results. Quarterly earnings reports significantly influence financial performance metrics and investor sentiment for Nyxoah SA.

Nyxoah SA (NYXH) reported a first-quarter net loss but surpassed revenue estimates. Q1 revenue beat despite net loss affects financial performance and market sentiment moderately.

Nyxoah SA (NYXH) may report negative earnings next week, with analysis highlighting historical trends ahead of the release. Expected negative earnings will moderately influence financial performance and investor sentiment.

Nyxoah's investment narrative shifts as CMS issues reimbursement codes for its sleep apnea therapy while analysts trim price targets amid ongoing challenges. CMS reimbursement codes represent a major regulatory win enhancing commercial prospects, tempered by analyst target cuts signaling execution risks.

Nyxoah detailed early U.S. launch plans for its Genio system and provided reimbursement updates at the Oppenheimer MedTech Conference 2026. Early U.S. Genio launch and reimbursement updates represent major steps toward market expansion and revenue growth.

Nyxoah SA (NYXH) Q4 2025 earnings call highlights strong U.S. launch success offset by financial challenges. U.S. launch success marks major market expansion with potential to boost revenue, despite financial headwinds.

Nyxoah (NYXH) Q4 2025 earnings call transcript details quarterly financial results, operational updates, revenue growth, and future guidance. Q4 earnings transcript reveals financial performance, strategic progress, and outlook, poised to significantly sway investor sentiment and stock trajectory.

Nyxoah SA's Q4 earnings call highlighted financial results, including revenue growth, operational updates, and forward guidance for the sleep apnea treatment company. Q4 earnings highlights disclose critical financial metrics, revenue performance, and strategic outlook that significantly shape investor expectations and stock trajectory.

Nyxoah SA (NYXH) reported a Q4 loss and missed revenue estimates. Q4 loss and revenue shortfall signal weaker financial results, moderately affecting investor sentiment and near-term performance.